



Atty Docket No.: R0032II-DIV
USSN: 10/731,607**Claim Listing**

66. (Currently Amended) A compound selected from the group of compounds represented by Formula I:



wherein:

R^1 is a group represented by formula (C):



wherein:

X is N;

R^2 and R^4 are each independently in each occurrence:

- (1) hydrogen,
- (2) alkyloxy, or
- (3) halogen;

R^6 is absent when X is S or O, and when X is N, R^6 is:

- (1) hydrogen,
- (2) $-\text{COR}^9$,
- (3) $-\text{CONR}^8\text{R}^9$,
- (4) $-\text{C(V)NR}^8\text{R}^9$ wherein V is O or S,
- (5) $-\text{SO}_2\text{R}^9$, or
- (6) $-\text{SO}_2\text{NR}^8\text{R}^9$;

Atty Docket No.: R0032H-DIV
USSN: 10/731,607

R^8 is independently in each occurrence:

- (1) hydrogen,
- (2) alkyl, or
- (3) hydroxyalkyl;

R^9 is independently in each occurrence:

- (1) alkyl,
- (2) cycloalkyl,
- (3) arylalkyl,
- (4) hydroxyalkyl,
- (5) haloalkyl,
- (6) heterocyclyl,
- (7) unsubstituted aryl or mono-, di-, or tri-substituted aryl, the substituents being independently selected from alkyl, halogen, or alkyloxy, or
- (8) heteroaryl; or

R^8 and R^9 are taken together with the nitrogen to which they are attached to form a 5- or 6-membered monocyclic saturated or unsaturated ring, and in which the ring is optionally substituted or unsubstituted with oxo; or a pharmaceutically acceptable salt ~~or a crystal form~~ thereof.

67. (Original) The compound of Claim 66 wherein R^2 and R^4 are each independently in each occurrence hydrogen or halogen.

68. (Original) The compound of Claim 2 wherein R^2 and R^4 are each independently hydrogen, fluoro or chloro.

69. (Currently Amended) The compound of Claim 68 wherein the pharmaceutically acceptable salt is selected from hydrochloride, sulfate or oxalate, ~~or a crystal form thereof~~.

Atty Docket No.: R0032H-DIV
USSN: 10/731,607

70. (Currently Amended) The compound of Claim 69 wherein the pharmaceutically acceptable salt is sulfate ~~or a crystal form thereof~~.

71. (Original) The compound of Claim 68 wherein R⁸ is hydrogen or alkyl, and R⁹ is alkyl or arylalkyl.

72. (Original) The compound of Claim 71 wherein R⁸ is hydrogen, methyl, ethyl or propyl, and R⁹ is methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, *sec*-butyl, *tert*-butyl or arylalkyl.

73. (Original) The compound of Claim 72 wherein R⁸ is hydrogen, methyl, ethyl or propyl, and R⁹ is alkyl or benzyl.

74 - 83 (Canceled)

84. (New) A pharmaceutical composition, comprising:

- (a) a compound of claim 66; and
- (b) a pharmaceutically acceptable carrier.

85. (New) A method for treating a urinary incontinence disease selected from urge incontinence, stress incontinence, and bladder hyperreactivity, the method comprising administering to a subject in need thereof an effective amount of a compound of claim 66.